Evidence map›Paper›PMID 25944533›Full record

ArticleThe Journal of antibiotics2015

Dibenzocyclooctadiene lignans from Schisandra spp. selectively inhibit the growth of the intracellular bacteria Chlamydia pneumoniae and Chlamydia trachomatis.

Elina Hakala, Leena Hanski, Hanna Uvell, Teijo Yrjönen, Heikki Vuorela, Mikael Elofsson, Pia Maarit Vuorela

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in The Journal of antibiotics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 32 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. AssayingMolecules (Basel, Switzerland) · 2020
    Article
  10. Potential ofNutrients · 2019
    Review
  11. Red FluorescentFrontiers in microbiology · 2018
    Article
  12. Article
  13. Review
  14. Current knowledge ofPhytochemistry reviews : proceedings of the Phytochemical Society of Europe · 2017
    Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Elina HakalaPharmaceutical Biology, CDR, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland.
Leena HanskiPharmaceutical Biology, CDR, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland.
Hanna UvellLaboratories for Chemical Biology Umeå, Department of Chemistry, Umeå University, Umeå, Sweden.
Teijo YrjönenPharmaceutical Biology, CDR, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland.
Heikki VuorelaPharmaceutical Biology, CDR, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland.
Mikael ElofssonLaboratories for Chemical Biology Umeå, Department of Chemistry, Umeå University, Umeå, Sweden.
Pia Maarit VuorelaPharmaceutical Biology, CDR, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland.
University of Helsinki · FIUmeå University · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lignans from Schisandra chinensis berries show various pharmacological activities, of which their antioxidative and cytoprotective properties are among the most studied ones. Here, the first report on antibacterial properties of six dibenzocyclooctadiene lignans found in Schisandra spp. is presented. The activity was shown on two related intracellular Gram-negative bacteria Chlamydia pneumoniae and Chlamydia trachomatis upon their infection in human epithelial cells. All six lignans inhibited C. pneumoniae inclusion formation and infectious progeny production. Schisandrin B inhibited C. pneumoniae inclusion formation even when administered 8 h post infection, indicating a target that occurs relatively late within the infection cycle. Upon infection, lignan-pretreated C. pneumoniae elementary bodies had impaired inclusion formation capacity. The presence and substitution pattern of methylenedioxy, methoxy and hydroxyl groups of the lignans had a profound impact on the antichlamydial activity. In addition our data suggest that the antichlamydial activity is not caused only by the antioxidative properties of the lignans. None of the compounds showed inhibition on seven other bacteria, suggesting a degree of selectivity of the antibacterial effect. Taken together, the data presented support a role of the studied lignans as interesting antichlamydial lead compounds.

Indexed as

Anti-Bacterial AgentsBacteriaCell LineChlamydia InfectionsChlamydia trachomatisChlamydophila pneumoniaeCyclooctanesHumansLignansMicrobial Sensitivity TestsPolycyclic CompoundsReactive Oxygen SpeciesSchisandraAnti-Bacterial AgentsCyclooctanesdibenzocyclooctadiene lignanLignansPolycyclic CompoundsReactive Oxygen Speciesschizandrin Aschizandrin B

Identifiers

PMID25944533
OpenAlexW1608931296

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.